A detailed history of Jump Financial, LLC transactions in Immatics N.V. stock. As of the latest transaction made, Jump Financial, LLC holds 33,600 shares of IMTX stock, worth $241,248. This represents 0.01% of its overall portfolio holdings.

Number of Shares
33,600
Previous 48,991 31.42%
Holding current value
$241,248
Previous $569,000 32.69%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.93 - $12.92 $168,223 - $198,851
-15,391 Reduced 31.42%
33,600 $383,000
Q2 2024

Aug 14, 2024

BUY
$9.78 - $13.49 $479,131 - $660,888
48,991 New
48,991 $569,000
Q4 2023

Oct 21, 2024

BUY
$7.36 - $10.89 $58,983 - $87,272
8,014 Added 19.8%
48,484 $510,000
Q4 2023

Feb 07, 2024

BUY
$7.36 - $10.89 $58,983 - $87,272
8,014 Added 19.8%
48,484 $510,000
Q3 2023

Oct 21, 2024

BUY
$11.01 - $12.62 $331,070 - $379,483
30,070 Added 289.13%
40,470 $468,000
Q3 2023

Nov 07, 2023

BUY
$11.01 - $12.62 $445,574 - $510,731
40,470 New
40,470 $468,000
Q1 2023

Oct 21, 2024

SELL
$6.74 - $9.44 $260,103 - $364,299
-38,591 Reduced 78.77%
10,400 $71,000
Q1 2023

May 03, 2023

SELL
$6.74 - $9.44 $92,338 - $129,328
-13,700 Reduced 56.85%
10,400 $71,000
Q4 2022

Feb 13, 2023

SELL
$8.05 - $11.58 $13,685 - $19,686
-1,700 Reduced 6.59%
24,100 $209,000
Q3 2022

Nov 07, 2022

BUY
$3.31 - $13.06 $25,420 - $100,300
7,680 Added 42.38%
25,800 $258,000
Q2 2022

Aug 09, 2022

BUY
$6.0 - $9.37 $34,920 - $54,533
5,820 Added 47.32%
18,120 $158,000
Q1 2022

May 12, 2022

SELL
$6.64 - $12.85 $17,928 - $34,695
-2,700 Reduced 18.0%
12,300 $98,000
Q4 2021

Feb 10, 2022

BUY
$10.81 - $14.38 $32,430 - $43,140
3,000 Added 25.0%
15,000 $202,000
Q3 2021

Nov 12, 2021

SELL
$11.58 - $15.46 $6,403 - $8,549
-553 Reduced 4.41%
12,000 $156,000
Q2 2021

Aug 13, 2021

BUY
$10.43 - $12.81 $130,927 - $160,803
12,553 New
12,553 $146,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $547M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.